Case Study

B Lymphocyte Surface Protein Complex & Hybridoma

The Challenge

To apply a multi-cohort immunization strategy with the IPA semi-solid hybridoma workflow, with high throughput multiplexed flow cytometry screening, to deliver a diverse panel of paralogue specific and species cross-reactive, lead candidate sequences.

Delivering a diverse panel of lead candidate sequences



Program Summary

Clones Screened	1° Hit Rate	Clones Sequenced	Unique %	Lead Candidates Selected
3840	344	31	92%	16

Phylogenetic Relationship of Top Clones



UID Designation

NZG = NZBW DNA
NZWC = NZBW whole cell
CDB = CD-1/BALB DNA
CDWC = CD-1 whole cell
SJL = SJL DNA

Conclusion

IPA's expertise in DNA and whole cell immunizations and semi-solid hybridoma workflow allowed for efficient NGS sequencing of parental clones leading to a diverse yet selective panel of lead candidates with an industry leading timeline.

For more information contact: info@ipatherapeutics.com

IpA

UNITED STATES | CANADA | EUROPE

ipatherapeutics.com